1. Inhibition of cancer growth and induction of apoptosis by BGP-13 and BGP-15, new calcipotriene-derived vitamin D₃ analogs, in-vitro and in-vivo studies

   • Amnon C. Sintov
   • Liron Berkovich
   • Shimon Ben-Shabat

   PRECLINICAL STUDIES 02 June 2012 Pages: 247 - 255

   

2. Tumor regression with a combination of drugs interfering with the tumor metabolism: efficacy of hydroxycitrate, lipoic acid and capsaicin

   • Laurent Schwartz
   • Adeline Guais
   • Mohammad Abolhassani

   PRECLINICAL STUDIES 14 July 2012 Pages: 256 - 264

   

3. The prostate cancer blocking potential of the histone deacetylase inhibitor LBH589 is not enhanced by the multi receptor tyrosine kinase inhibitor TKI258

   • Stefan Vallo
   • Jens Mani
   • Roman A. Blaheta

   PRECLINICAL STUDIES 17 July 2012 Pages: 265 - 272

   

4. The vascular disrupting agent ombrabulin (AVE8062) enhances the efficacy of standard therapies in head and neck squamous cell carcinoma xenograft models

   • Céline Clémenson
   • Erwan Jouannot
   • Eric Deutsch

   PRECLINICAL STUDIES 19 July 2012 Pages: 273 - 284

   

5. Efficacy of substituted 9-aminoacridine derivatives in small cell lung cancer

   • Etchison Ryan
   • A. Jacobson Blake
   • A. Kratzke Robert

   PRECLINICAL STUDIES 22 July 2012 Pages: 285 - 292

   

6. Mechanisms of acquired resistance to insulin-like growth factor 1 receptor inhibitor in MCF-7 breast cancer cell line

   • Roudy Chiminch Ekyalongo
   • Toru Mukohara
   • Hironobu Minami

   PRECLINICAL STUDIES 25 July 2012 Pages: 293 - 303

   

7. Vascular disrupting activity and the mechanism of action of EHT 6706, a novel anticancer tubulin polymerization inhibitor

   • Anne-Sophie Belzacq-Casagrande
   • Florence Bachelot
   • Laurent Désiré

   PRECLINICAL STUDIES 10 August 2012 Pages: 304 - 319

   

8. Inhibition of topoisomerase II α activity and induction of apoptosis in mammalian cells by semi-synthetic andrographolide analogues

   • Jintapat Nateewattana
   • Rungnapha Saeeng
   • Pawinee Piyachaturawat

   PRECLINICAL STUDIES 17 August 2012 Pages: 320 - 332

   

9. Enhanced killing of cervical cancer cells by combinations of methyl jasmonate with cisplatin, X or alpha radiation

   • Elad Milrot
   • Anna Jackman
   • Levana Sherman

   PRECLINICAL STUDIES 06 September 2012 Pages: 333 - 344

   

10. Phase I pharmacokinetic and pharmacodynamic study of cetuximab, irinotecan and sorafenib in advanced colorectal cancer

    • Nilofer Azad
    • Arvind Dasari
    • Wells A. Messersmith

    PHASE I STUDIES 22 May 2012 Pages: 345 - 354

    

11. A Phase I trial of the kinesin spindle protein (Eg5) inhibitor AZD4877 in patients with solid and lymphoid malignancies

    • John F. Gerecitano
    • Joe J. Stephenson
    • Gary K. Schwartz

    PHASE I STUDIES 22 May 2012 Pages: 355 - 362

    

12. Unexpected renal toxicity associated with SGX523, a small molecule inhibitor of MET

    • Jeffrey R. Infante
    • Terence Rugg
    • Ramesh K. Ramanathan

    PHASE I STUDIES 01 May 2012 Pages: 363 - 369

    

13. Phase I study of barasertib (AZD1152), a selective inhibitor of Aurora B kinase, in patients with advanced solid tumors

    • Gary K. Schwartz
    • Richard D. Carvajal
    • Geoffrey I. Shapiro

    PHASE I STUDIES 02 June 2012 Pages: 370 - 380

    

14. Eribulin mesylate pharmacokinetics in patients with solid tumors receiving repeated oral ketoconazole

    • L. A. Devriese
    • M. Mergui-Roelvink
    • J. H. M. Schellens

    PHASE I STUDIES 05 May 2012 Pages: 381 - 389

    

15. A phase I, dose-finding study of sunitinib combined with cisplatin and 5-fluorouracil in patients with advanced gastric cancer

    • C. Gómez-Martín
    • R. Salazar
    • J. Bellmunt

    PHASE I STUDIES 22 May 2012 Pages: 390 - 398

    

16. A Phase I, open-label, dose escalation study of afatinib, in a 3-week-on/1-week-off schedule in patients with advanced solid tumors

    • John Marshall
    • Jimmy Hwang
    • Nancy L Lewis

    PHASE I STUDIES Open access 17 November 2012 Pages: 399 - 408

    

17. A Phase I, open-label, dose-escalation study of continuous once-daily oral treatment with afatinib in patients with advanced solid tumors

    • Michael S. Gordon
    • David S. Mendelson
    • David B. Agus

    PHASE I STUDIES Open access 15 December 2012 Pages: 409 - 416

    

18. Phase II trial of single-agent foretinib (GSK1363089) in patients with recurrent or metastatic squamous cell carcinoma of the head and neck

    • Tanguy Seiwert
    • John Sarantopoulos
    • George Blumenschein Jr.

    PHASE II STUDIES Open access 24 August 2012 Pages: 417 - 424

    

19. Phase I/II study of pegylated arginine deiminase (ADI-PEG 20) in patients with advanced melanoma

    • Patrick A. Ott
    • Richard D. Carvajal
    • Jedd D. Wolchok

    PHASE II STUDIES 05 August 2012 Pages: 425 - 434

    

20. Pre-operative chemoradiation followed by post-operative adjuvant therapy with tetrathiomolybdate, a novel copper chelator, for patients with resectable esophageal cancer

    • Bryan J. Schneider
    • Julia Shin-Jung Lee
    • Susan G. Urba

    PHASE II STUDIES 31 July 2012 Pages: 435 - 442

    

21. Population pharmacokinetic modeling of Sepantronium bromide (YM155), a small molecule survivin suppressant, in patients with non-small cell lung cancer, hormone refractory prostate cancer, or unresectable stage III or IV melanoma

    • Yumiko Aoyama
    • Atsunori Kaibara
    • Taiji Sawamoto

    PHASE II STUDIES Open access 16 August 2012 Pages: 443 - 451

    

22. The inhibitor of Ca²⁺-dependent K⁺ channels TRAM-34 blocks growth of hepatocellular carcinoma cells via downregulation of estrogen receptor alpha mRNA and nuclear factor-kappaB

    • Christian Freise
    • Martin Ruehl
    • Rajan Somasundaram

    Short Report 02 October 2012 Pages: 452 - 457

    

23. The non-genotoxic activator of the p53 pathway Nutlin-3 shifts the balance between E2F7 and E2F1 transcription factors in leukemic cells

    • Maria Grazia di Iasio
    • Giorgio Zauli

    SHORT REPORT 02 October 2012 Pages: 458 - 460

    

24. The PARP inhibitor ABT-888 synergizes irinotecan treatment of colon cancer cell lines

    • David Davidson
    • Yunzhe Wang
    • Lawrence Panasci

    SHORT REPORT 09 October 2012 Pages: 461 - 468

    

25. Gemcitabine alone and/or containing chemotherapy is efficient in refractory or relapsed NK/T-cell lymphoma

    • Hee Kyung Ahn
    • Seok Jin Kim
    • Won Seog Kim

    SHORT REPORT 28 October 2012 Pages: 469 - 472

    

26. Differences in drug approval processes of 3 regulatory agencies: a case study of gemtuzumab ozogamicin

    • Tetsuya Tanimoto
    • Masaharu Tsubokura
    • Masahiro Kami

    REVIEW 11 September 2012 Pages: 473 - 478

    

27. Clinical trial design in biosimilar drug development

    • G. Dranitsaris
    • K. Dorward
    • E. Amir

    REVIEW 17 November 2012 Pages: 479 - 487

    

28. Erratum to: Silymarin attenuated mast cell recruitment thereby decreased the expressions of matrix metalloproteinases-2 and 9 in rat liver carcinogenesis

    • Gopalakrishnan Ramakrishnan
    • Sundaram Jagan
    • Thiruvengadam Devaki

    Erratum 31 October 2012 Pages: 488 - 489

    

29. Erratum to: Inhibition of cancer growth and induction of apoptosis by BGP-13 and BGP-15, new calcipotriene-derived vitamin D₃ analogs, in-vitro and in-vivo studies

    • Liron Berkovich
    • Amnon C. Sintov
    • Shimon Ben-Shabat

    Erratum 16 January 2013 Pages: 490 - 490

30. Acknowledgement of Reviewers 2011

    Acknowledgments 20 December 2012 Pages: 491 - 492